Results 51 to 60 of about 1,817,538 (306)

Targeted therapy in lymphoma [PDF]

open access: yes, 2010
Discovery of new treatments for lymphoma that prolong survival and are less toxic than currently available agents represents an urgent unmet need. We now have a better understanding of the molecular pathogenesis of lymphoma, such as aberrant signal ...
Patrick B Johnston   +3 more
core   +1 more source

Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. [PDF]

open access: yes, 2020
Hundreds of trials are being conducted to evaluate combination of newer targeted drugs as well as immunotherapy. Our aim was to compare efficacy and safety of combination versus single non-cytotoxic anticancer agents. We searched PubMed (01/01/2001 to 03/
Barkauskas, Donald A   +4 more
core   +1 more source

Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Objective To evaluate selumetinib exposure using therapeutic drug monitoring (TDM) in pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN), assess interpatient pharmacokinetic variability, and explore the relationship between drug exposure, clinical response, and adverse effects.
Janka Kovács   +8 more
wiley   +1 more source

Circular RNA circBNC2 inhibits tumorigenesis by modulating ferroptosis and acts as a nanotherapeutic target in prostate cancer

open access: yesMolecular Cancer
Background Metastasis is a leading cause of cancer-related death in castration-resistant prostate cancer (CRPC) patients. Circular RNAs (circRNAs) have emerged as key regulators of the metastasis of various cancers.
Xiang Pan   +10 more
doaj   +1 more source

Measurement of the effect of digital play therapy using biological information [PDF]

open access: yes, 2017
We developed the new therapy device named "Digital Play Therapy Device", which combines house-shaped device with sensors attached and CG. The device was targeted for children with learning disabilities.
Giannopulu, Irini   +3 more
core   +1 more source

Sirolimus for Extracranial Arteriovenous Malformations: A Scoping Review of the Evidence in Syndromic and Non‐Syndromic Cases

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Arteriovenous malformations (AVMs) are rare, high‐flow, vascular anomalies that can occur either sporadically or as part of a genetic syndrome. AVMs can progress with serious morbidity and even mortality if left unchecked. Sirolimus is an mTOR inhibitor that is effective in low‐flow vascular malformations; however, its role in AVMs is unclear.
Will Swansson   +3 more
wiley   +1 more source

Circular RNA circSLC39A10 promotes prostate cancer progression by activating Wnt signaling via the miR-936/PROX1/β-catenin axis

open access: yesCellular & Molecular Biology Letters
Circular RNAs (circRNAs) play a crucial role in the initiation and development of cancers. Understanding circRNAs’ functions and molecular mechanisms in tumor development is expected to reveal new diagnostic indicators and therapeutic targets of prostate
Kailai Chen   +10 more
doaj   +1 more source

Evaluating the Utility of Paired Tumor and Germline Targeted DNA Sequencing for Pediatric Oncology Patients: A Single Institution Report

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Objective To evaluate the diagnostic yield and utility of universal paired tumor–normal multigene panel sequencing in newly diagnosed pediatric solid and central nervous system (CNS) tumor patients and to compare the detection of germline pathogenic/likely pathogenic variants (PV/LPVs) against established clinical referral criteria for cancer ...
Natalie Waligorski   +9 more
wiley   +1 more source

Exploring RNA-targeted gene therapy approaches for hypertrophic cardiomyopathy [PDF]

open access: yes, 2012
Relatório de projeto no âmbito do Programa de Bolsas Universidade de Lisboa/Fundação Amadeu Dias (2011/2012). Universidade de Lisboa.
Freitas, Ana
core  

Intravitreal GD2‐Specific Chimeric Antigen Receptor T‐Cell Therapy for Refractory Retinoblastoma

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Effective treatments for advanced, treatment‐resistant retinoblastoma (RB) remain limited. GD2‐specific chimeric antigen receptor (CAR) T cells show potent antitumor activity with minimal toxicity but have not previously been evaluated in RB.
Subongkoch Subhadhirasakul   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy